

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

Surface-specific bone formation effects of osteoporosis pharmacological treatments

Matthew R. Allen

Department of Anatomy and Cell Biology, Indiana University School of Medicine,
Indianapolis, IN 46202

Disclosures: Dr. Allen has research contracts with Eli Lilly, The Alliance for Better Bone Health, and Amgen. He also serves as a consultant for Merck and Co.

Corresponding Author:

Matthew R. Allen
Dept of Anatomy & Cell Biology
635 Barnhill Drive, MS-5035
Indianapolis, IN 46202
Tel: (317) 274-1283
FAX: (317) 278-2040
Email: matallen@iupui.edu

This is the author's manuscript of the article published in final edited form as: Allen M. R. (2008). Surface-specific bone formation effects of osteoporosis pharmacological treatments, *Clinical Reviews in Bone and Mineral Metabolism*, 6(1-2): 62-9. Available from: <http://dx.doi.org/10.1007/s12018-008-9022-6>

Abstract

Current anti-osteoporotic pharmacological treatments reduce fracture risk in part by altering bone remodeling/modeling. These effects can manifest on any or all of the bone envelopes – periosetal, intracortical, and trabecular/endocortical – each of which has unique effects on the biomechanical properties of bone. The purpose of this review is to provide an overview of how the most common FDA-approved anti-osteoporosis agents (bisphosphonates, estrogen/hormone replacement therapy, selective estrogen receptor modulators (SERMs), and parathyroid hormone (PTH)) affect tissue-level remodeling/modeling on each of the bone surfaces. Iliac crest biopsy data, the only means of assessing surface-specific bone formation in humans, exist for all of these agents although they predominately focus on trabecular/endocortical surfaces. Data from pre-clinical animal models provide an essential complement to human studies, particularly for changes on periosteal surfaces and within the intracortical envelope. Although all of the anti-catabolic agents (estrogen replacement therapy, SERMs, bisphosphonates) exert positive effects on the various bone surfaces, the bisphosphonates produce the unique biomechanical combination of allowing normal periosteal expansion while limiting remodeling-induced bone loss on intracortical and trabecular/endocortical surfaces. PTH, the only FDA-approved anabolic agent, exerts biomechanically favorable alterations though enhanced trabecular/endocortical surface activity while also stimulating periosetal expansion. Through understanding how current and future anti-osteoporotic agents influence surface-specific bone activity we will move one step closer to developing agents that could potentially target a particular bone surface.

49 **Key words:** bisphosphonates, estrogen/hormone replacement therapy, selective estrogen
50 receptor modulators (SERMs), parathyroid hormone
51

Introduction

Current osteoporosis pharmacological treatments are highly effective in reducing fracture risk [1-3]. The mechanisms underlying fracture risk reduction with the various treatments is not completely understood but is due in large part to the effect these agents have on bone remodeling/modeling. Bone remodeling, the coupled process of bone resorption and formation, serves to renew bone tissue and occurs on trabecular and endocortical bone surfaces and within the cortex (intracortical remodeling) (**Fig. 1**).

Bone modeling, an uncoupled process in which formation or resorption occur independent of the other, occurs on trabecular, endocortical, and periosteal surfaces.

Anti-osteoporotic agents can be classified as anti-catabolic or anabolic [4]. Anti-catabolic agents, including bisphosphonates, estrogen/hormone replacement therapy (HRT), selective estrogen receptor modulators (SERMs), and calcitonin work primarily by suppressing bone remodeling. Remodeling suppression slows bone loss, preserving bone architecture and geometry. The only anabolic agent currently approved for treating osteoporosis, parathyroid hormone (PTH), stimulates both modeling and remodeling which preserves, and in some cases enhances, bone architecture and geometry. While the modeling/remodeling effect of each anti-catabolic and anabolic agent is important, the surface(s) on which the effects occur are perhaps more important for bone biomechanics and fracture risk reduction.

The purpose of this review is to provide an overview of how the FDA-approved anti-osteoporosis agents affect tissue-level remodeling/modeling on each of the bone

envelopes - periosteal, intracortical, and endocortical/trabecular - and how this is likely to influence bone biomechanics. As a limited amount of human data exist (from bone biopsy analyses), the majority of information comes from pre-clinical animal studies. This results in a certain degree of ambiguity with respect to determining how each agent affects the various surfaces as differences among studies, such as species, treatment (dose and duration), and whether or not the animals are intact or ovariectomized, all influence remodeling/modeling effects. Therefore, for each of the bone surfaces, the effects of the various treatments will be summarized for humans, intact animals, and ovariectomized animals, the latter two categories focusing mostly on large animal models.

Periosteal surface

Periosteal bone surfaces primarily undergo modeling which is most prominent during growth and development yet continues at a slower rate in adults [5]. Remodeling does occur on periosteal surfaces [6-8] but is generally considered to constitute a small percentage of overall activity on this surface. The addition of bone to the periosteal surface exponentially enhances bone biomechanical properties by increasing the cross-sectional moment of inertia [7, 9]. This is true both for bones made exclusively of cortical bone (e.g. long bone diaphysis) and for those with significant amounts of trabecular bone (e.g. vertebra and femoral neck) [10]. The clinical implications of periosteal expansion are significant as only a small amount of bone needs to be added to this surface to enhance the biomechanical properties [7, 11]. Periosteal expansion can also offset the negative biomechanical effects associated with bone loss from other bone envelopes as only 30% of bone mass lost from the endocortical surface needs to be added

to the periosteal surface to achieve equivalent biomechanical properties [11]. Despite the substantial biomechanical benefit of periosteal apposition, very little clinical data exists concerning the effects of anti-osteoporosis pharmaceutical agents on this surface.

Loss of estrogen increases periosteal expansion while estrogen supplementation suppresses expansion [12-15]. Ample histological data exist concerning the effects of hormone/estrogen replacement therapy (HRT) in humans yet they do not routinely include analyses of the periosteal surface. The available data, published only in abstract form, suggest reduced periosteal formation with HRT [16]. There is no data on the effects of selective estrogen receptor modulators (SERMs) on periosteal bone formation. Raloxifene, one of the most commonly studied SERMs, had no effect on femoral periosteal bone formation in ovariectomized cynomolgus monkeys suggesting it does not inhibit periosteal expansion in estrogen-deplete situations [15]. Conversely, in an intact beagle dog model where endogenous estrogen levels are normal, raloxifene significantly enhanced periosteal bone formation rate compared to controls [17].

Bisphosphonates exert their skeletal effect through suppression of remodeling and therefore would be expected to have minimal direct effect on periosteal surfaces. Clinical data describing bone formation activity on periosteal surfaces, published only in abstract form, suggest no effect of alendronate on the periosteal surface of iliac crest biopsies [16, 18]. Pre-clinical studies with intact beagles [17, 19-21], ovariectomized beagles [22], and intact minipigs [23] have consistently shown no significant effect of bisphosphonates on periosteal bone formation. Significant suppression of periosteal bone formation has been

shown in several rodent studies [24-26] although the absence of similar data in larger pre-clinical models or humans suggest this may a species-specific effect.

As an anabolic agent, intermittent PTH (teriparatide, synthetic PTH [hPTH(1-34)], recombinant human teriparatide [rhPTH(1-34)], or PTH(1-84)), would be expected to have the greatest effect of all the approved osteoporosis agents on periosteal bone [3, 27]. While iliac crest biopsy samples from PTH-treated patients consistently show increased cortical thickness compared to placebo-treated patients [28-31], periosteal surface bone formation results have been conflicting. Following 1 month of treatment, periosteal bone formation rate was significantly higher than controls [32] showed no significant difference between PTH- and placebo-treated patients [28, 33]. Intact rabbits, the only large animal model in which periosteal bone responses to PTH have been examined, have shown significantly higher periosteal bone formation with PTH treatment compared to vehicle [34-36].

Summary- Periosteal surfaces (Table 1)

Periosteal expansion has a significant effect on fracture risk yet there are minimal data describing how anti-osteoporosis agents influence activity on this surface. Beginning at menopause, the loss of endogenous estrogen stimulates periosteal expansion. Estrogen/hormone replacement therapy suppresses this periosteal expansion while bisphosphonates have no effect. The human data concerning SERMs and PTH on periosteal bone are insufficient to draw conclusions concerning their effects although

some clinical and the majority of pre-clinical data suggest an anabolic effect (or at worst no effect) with PTH.

Intracortical envelope

The bone cortex of humans and many large animal research models (non-human primates, dogs, pigs, rabbits) routinely undergoes intracortical (osteonal) [37, 38]. Similar to trabecular bone remodeling, the loss of estrogen at menopause is associated with an imbalance in the amount of bone formation relative to resorption within intracortical remodeling units. This negative bone balance, coupled with the increases in intracortical remodeling, result in high levels of cortical porosity in postmenopausal women. Intracortical porosity is inversely related to mechanical properties [39, 40] yet its effect is highly dependent on the spatial location of the pores. In bending or torsion, cortical porosity near the outer periosteal surface has a greater negative effect on biomechanics as compared to if the voids are near the endocortical surface [34, 39]. As with the periosteal surface, few clinical data exist concerning the effects of pharmaceutical agents on intracortical remodeling emphasizing the importance of pre-clinical models. In the case of intracortical remodeling, pre-clinical models are limited exclusively to large animal models as under normal physiological conditions rodents lack intracortical remodeling.

Reductions in circulating estrogen increase cortical porosity through stimulation of intracortical remodeling [15, 22, 41]. In response to drug-induced or naturally occurring reductions in circulating estrogen, HRT inhibited increased intracortical remodeling and

cortical porosity [41, 42]. Similar results have been noted in non-human primates wherein intracortical remodeling increased with estrogen withdrawal leading to increases in cortical porosity [15]. These increases in remodeling and porosity were reduced in animals treated with either estrogen or raloxifene [15]. Treatment of intact beagles with raloxifene had no effect on intracortical remodeling [17].

Bisphosphonates, due to their suppression of remodeling, would be expected to suppress intracortical remodeling. Human data are limited and conflicting. Following 1 to 3 years of risedronate treatment, iliac crest cortical porosity was not different compared to baseline levels or age-matched placebo controls [43, 44]. Conversely, biopsies from women treated for 2-3 years with alendronate had significantly lower cortical porosity in the iliac crest compared to placebo-treated patients [45]. Pre-clinical models consistently document reductions in intracortical remodeling with bisphosphonates. In ovariectomized non-human primates clodronate suppressed tibia intracortical bone formation to control levels [46] while ibandronate reduced intracortical remodeling in the rib and central radius, but not the femoral neck, compared to controls [47]. Suppression of intracortical turnover with bisphosphonates has also been shown in ovariectomized beagles [22], intact beagles [19, 21, 48], and intact minipigs [23].

Of the approved osteoporosis treatments, PTH has the most distinct effect on intracortical remodeling. Using intact female rabbits, PTH has been shown to produce a rapid increase (within the first remodeling cycle) of intracortical bone remodeling [36] which is sustained with continued treatment [35, 36]. This stimulation of remodeling leads to a

significant increase in cortical porosity [35, 36]. While an increase in porosity would be predicted to reduce biomechanical properties, the preferential location of intracortical remodeling and porosity near the endocortical surface with PTH minimized any negative biomechanical effects. For example, the increased porosity near the endocortical surface with PTH compromised the cross-sectional moment of inertial (CSMI; an index of biomechanical strength) by less than 2%; if this same amount of porosity were located near the periosteal surface the CSMI would be reduced by almost 10% [35]. Similar results have been documented in ovariectomized non-human primates where intracortical turnover rate was significantly increased in the femur [49], humerus [50], and femoral neck [49] following PTH treatment. The increased porosity with PTH in these non-human primate studies was most notable near the endocortical surface [50], as with the rabbits, and therefore resulted in only minimal consequences to the biomechanical properties of these bones [50]. Increases in cortical porosity with PTH have also been shown in an intact dog model suggesting that similar changes within the cortex occur with PTH treatment when estrogen levels are normal [51]. Human data concerning changes with PTH are limited, yet the porosity data are not consistent with pre-clinical studies. Paired iliac crest biopsies from PTH-treated patients showed a trend toward increased porosity [30] although there was clearly no effect in two other studies of PTH-treatment [28, 29]; these clinical studies did not assess intracortical remodeling.

Summary- Intracortical envelope (Table 1)

Intracortical remodeling increases during menopause, leading to higher levels of cortical porosity which reduces biomechanical properties. Anti-catabolic osteoporosis agents,

HRT, SERMs, and bisphosphonates, appear to suppress intracortical remodeling and therefore reduce cortical porosity. Several large animal models show PTH stimulates intracortical remodeling and increases cortical porosity, the biomechanical consequences of which are minimized through preferential location of such activity near the endocortical surface. Based on these data, the anti-catabolic agents provide the most favorable effect on intracortical bone as they reduce cortical porosity in postmenopausal women. However anabolic agents are also attractive for this bone envelope as enhanced remodeling would serve to renew bone tissue and occur spatially such that it has minimal consequences to biomechanics.

Trabecular/Endocortical surfaces

At menopause, bone remodeling increases on trabecular and endocortical surfaces [52-54] resulting in a significant loss of bone volume and trabecular architecture [44, 55]. Bone formation activity on the trabecular surface is the most studied of the bone envelopes however it is the most complex surface to assess how remodeling/modeling influences biomechanics due to the intimate relationship between trabecular and cortical bone. There is a clear biomechanical benefit of increasing trabecular bone volume with the enhancement of trabecular number having a greater benefit compared to increasing trabecular thickness [56]. Equally important to biomechanics is having a well-connected trabecular network. Therefore, changes in both bone volume and architecture likely determine the ultimate biomechanical effect of anti-osteoporosis treatments on trabecular bone.

The effect of HRT on trabecular surface activity is conflicting. HRT has been shown to significantly suppress trabecular bone remodeling in the majority of human studies [54, 57-60] although other studies have shown no effect [61-64]. Similar discrepancies exist for the effects of HRT on bone volume and architecture with one study showing beneficial effects [62] and others showing no effect [58, 60, 63, 64]. Data from humans treated with SERMs have provided more consistent results compared to HRT, having shown significant [54, 65] and non-significant [58] reductions in trabecular bone remodeling with raloxifene compared to controls. Ovariectomized non-human primates had significantly lower trabecular and endocortical bone formation rates at the iliac crest, vertebra, and tibia when treated with either estrogen or raloxifene [15, 66]. Intact beagle dogs have non-significantly lower trabecular bone remodeling with raloxifene [67].

Studies examining the effect of bisphosphonates on trabecular bone remodeling and bone volume consistently show significant suppression of bone remodeling on both trabecular and endocortical surfaces [43, 68-71]. These reductions in remodeling with bisphosphonate treatment are associated with prevention of the normal loss of bone volume and architecture in placebo-treated patients [43, 44, 55, 71, 72]. Pre-clinical models similarly show that bisphosphonates suppress remodeling and increase bone volume in ovariectomized non-human primates [46, 47, 73], ovariectomized beagles [22, 74], intact minipigs [23], and intact beagles [17, 21, 48, 73, 75-79].

In contrast to anti-catabolic agents, PTH has anabolic effects on trabecular bone formation which are modulated through both bone modeling and remodeling activity

[80]. PTH stimulates trabecular surface modeling [32, 81-83] and affects remodeling by altering the balance at each remodeling site to favor bone formation [28, 51]. Enhancement of trabecular bone volume and bone remodeling have been shown in postmenopausal women treated with intermittent PTH [29, 32, 84] although other studies have shown no significant difference from baseline biopsies in PTH-treated patients for trabecular formation activity or bone mass [28, 85]. In ovariectomized non-human primates, multiple skeletal sites (femoral neck, tibia, distal radius, and vertebra) showed no difference in PTH versus controls for trabecular bone formation rate although bone formation was stimulated on endocortical surfaces of the mid-radius and mid-femur [86]. Conversely, a separate study showed enhanced bone formation activity on trabecular bone surfaces of the femoral neck with PTH [49]. Changes with PTH treatment are most consistent in intact animals, with increases in trabecular/endocortical bone remodeling having been documented in ewes [87], beagles [51, 88], and rabbits [35, 36]. These pre-clinical models have shown enhancement of trabecular bone formation activity with PTH results in increased trabecular bone volume by initially producing thicker trabeculae, and then over time via trabecular tunneling [89], normalizing trabecular thickness and enhancing trabecular number and connectivity [28, 30, 88, 90].

Summary- Trabecular/Endocortical surfaces (Table 1)

Enhanced trabecular/endocortical remodeling at menopause leads to loss of bone mass and architectural integrity. Anti-catabolic osteoporosis agents, HRT, SERMs, and bisphosphonates, suppress remodeling and result in maintenance of trabecular bone volume and architecture. By suppressing the deterioration of trabecular bone, these

agents all maintain the biomechanical integrity of skeletal sites containing appreciable amounts of trabecular bone. Conversely, anabolic treatment with PTH enhances bone formation activity on trabecular surfaces which positively affects trabecular bone volume and architecture. Based on these effects, both anti-catabolic and anabolic agents have value for trabecular/endocortical bone with the optimal choice depending on whether the goal of treatment is slowing deterioration (anti-catabolic agents) or actively enhancing (anabolic) bone mass and architecture.

Conclusions

Alterations to bone formation activity on the periosteal, intracortical, and trabecular/endocortical surfaces imparted by anti-osteoporosis treatments have unique influences on bone biomechanics. Although all of the anti-catabolic agents (estrogen/hormone replacement therapy, SERMs, bisphosphonates) exert positive effects on the various bone surfaces, bisphosphonates provide a unique biomechanical combination by allowing normal periosteal expansion while limiting bone loss on intracortical and trabecular/endocortical surfaces. PTH, the only FDA-approved anabolic, also exerts biomechanically favorable alterations to bone formation on the various bone surfaces through enhanced activity on trabecular/endocortical surfaces combined with allowing normal periosteal expansion. As new agents gain approval for treatment postmenopausal osteoporosis it will be advantageous to understand how they each affect the various bone surfaces in order to determine the mechanism(s) through which they reduce fracture risk. Equally, if not more important is that this information will help advance our understanding of surface-specific regulation of bone formation

304 which ideally can be utilized to design agents that specifically target a particular bone
305 surface.

306

307

308 **Table 1. Summary of pharmaceutical effects on surface-specific bone formation***

	Estrogen/Hormone Replacement Therapy	Selective Estrogen Receptor Modulators	Bisphosphonates	Parathyroid Hormone
Periosteal				
Postmenopausal women	Decrease	--	No effect	Increase
Ovariectomized animals	Decrease	No effect	No effect	--
Intact animals	Decrease	Increase	No effect	Increase
Intracortical				
Postmenopausal women	Decrease	--	No effect / Decrease	--
Ovariectomized animals	Decrease	Decrease	Decrease	Increase
Intact animals	--	No effect	Decrease	Increase
Endocortical/Trabecular				
Postmenopausal women	Decrease	Decrease	Decrease	Increase
Ovariectomized animals	Decrease	Decrease	Decrease	Increase
Intact animals	--	Decrease	Decrease	Increase

309

310 *In cases where conflicting data exist (see text), the stated effect represents the majority
 311 response. (--) signifies there are no data available.

312

Figure Legends

Fig. 1. Anti-osteoporosis pharmaceutical agents impart their skeletal effects in part by altering bone remodeling/modeling on periosteal (B, arrowhead), intracortical (B, arrow), trabecular (C), and endocortical (D) bone surfaces. Scale bar = 1 mm (A) or 500 μ m (B-D).

321 **References**

- 322 1. Cummings, S.R., D.B. Karpf, F. Harris, H.K. Genant, et al., Improvement in spine
323 bone density and reduction in risk of vertebral fractures during treatment with
324 antiresorptive drugs. 2002 Am J Med. 112(4): p. 281-9.
- 325 2. Marcus, R., M. Wong, H. Heath, 3rd, and J.L. Stock, Antiresorptive treatment of
326 postmenopausal osteoporosis: comparison of study designs and outcomes in large
327 clinical trials with fracture as an endpoint. 2002 Endocr Rev. 23(1): p. 16-37.
- 328 3. Rosen, C. and J. Bilezikian, Anabolic therapy for osteoporosis. 2001 J Clin
329 Endocrinol Metab. 86(3): p. 957-964.
- 330 4. Riggs, B.L. and A.M. Parfitt, Drugs used to treat osteoporosis: the critical need
331 for a uniform nomenclature based on their action on bone remodeling. 2005 J
332 Bone Miner Res. 20(2): p. 177-84.
- 333 5. Allen, M.R., J.M. Hock, and D.B. Burr, Periosteum: biology, regulation, and
334 response to osteoporosis therapies. 2004 Bone. 35(5): p. 1003-1012.
- 335 6. Bliziotis, M., J.D. Sibonga, R.T. Turner, and E. Orwoll, Periosteal remodeling at
336 the femoral neck in nonhuman primates. 2006 J Bone Miner Res. 21(7): p. 1060-
337 7.
- 338 7. Orwoll, E., Toward an expanded understanding of the role of the periosteum in
339 skeletal health. 2003 J Bone Miner Res. 18(6): p. 949-954.
- 340 8. Balena, R., M.S. Shih, and A.M. Parfitt, Bone resorption and formation on the
341 periosteal envelope of the ilium: a histomorphometric study in healthy women.
342 1992 J Bone Miner Res. 7(12): p. 1475-82.
- 343 9. Ahlborg, H., O. Johnell, C. Turner, G. Rannevik, et al., Bone loss and bone size
344 after menopause. 2003 N Engl J Med. 349(4): p. 327-34.
- 345 10. Beck, T.J., C.B. Ruff, W.W. Scott, Jr., C.C. Plato, et al., Sex differences in
346 geometry of the femoral neck with aging: a structural analysis of bone mineral
347 data. 1992 Calcif Tissue Int. 50(1): p. 24-9.
- 348 11. Burr, D.B. and C.H. Turner, *Biomechanics of bone*, in *Primer on the Metabolic*
349 *Bone Diseases and Disorders of Mineral Metabolism*, M. Favus, Editor. 2003,
350 American Society for Bone and Mineral Research: Washington DC. p. 58-64.
- 351 12. Turner, R.T., B.L. Riggs, and T.C. Spelsberg, Skeletal effects of estrogen. 1994
352 Endocr Rev. 15(3): p. 275-300.
- 353 13. Turner, R.T., K.S. Hannon, L.M. Demers, J. Buchanan, et al., Differential effects
354 of gonadal function on bone histomorphometry in male and female rats. 1989 J
355 Bone Miner Res. 4(4): p. 557-63.
- 356 14. Wakley, G.K., G.L. Evans, and R.T. Turner, Short-term effects of high dose
357 estrogen on tibiae of growing male rats. 1997 Calcif Tissue Int. 60(1): p. 37-42.
- 358 15. Lees, C.J., T.C. Register, C.H. Turner, T. Wang, et al., Effects of raloxifene on
359 bone density, biomarkers, and histomorphometric and biomechanical measures in
360 ovariectomized cynomolgus monkeys. 2002 Menopause. 9(5): p. 320-8.
- 361 16. Recker, R., T. Coble, A. Burshell, A. Lombardi, et al., Effect of Alendronate and
362 Estrogen Replacement on Periosteal Bone Formation in Postmenopausal Women.
363 2001 J Bone Miner Res. 16: p. 1176.

- 364 17. Allen, M.R., H. Follet, M. Khurana, and D.B. Burr, Anti-remodeling agents
365 influence osteoblast activity differently in modeling- and remodeling-associated
366 bone formation 2006 *Calcified Tissue International*. 79(4): p. 255-61.
- 367 18. Bare, S., S. Recker, R. Recker, and D. Kimmel, Influence of alendronate on
368 periosteal and endocortical bone formation in the ilium of osteoporotic women.
369 2005 *J Bone Miner Res*. 20: p. SA414.
- 370 19. Mashiba, T., T. Hirano, C.H. Turner, M.R. Forwood, et al., Suppressed bone
371 turnover by bisphosphonates increases microdamage accumulation and reduces
372 some biomechanical properties in dog rib. 2000 *J Bone Miner Res*. 15(4): p. 613-
373 20.
- 374 20. Komatsubara, S., S. Mori, T. Mashiba, J. Li, et al., Suppressed bone turnover by
375 long-term bisphosphonate treatment accumulates microdamage but maintains
376 intrinsic material properties in cortical bone of dog rib. 2004 *J Bone Miner Res*.
377 19(6): p. 999-1005.
- 378 21. Allen, M.R., S. Reinwald, and D.B. Burr, Alendronate reduces bone toughness of
379 ribs without significantly increasing microdamage accumulation in dogs
380 following 3 years of daily treatment. 2008 *Calcif Tissue Int*. May 8 [Epub ahead
381 of print].
- 382 22. Yoshida, Y., A. Moriya, K. Kitamura, M. Inazu, et al., Responses of trabecular
383 and cortical bone turnover and bone mass and strength to bisphosphonate YH529
384 in ovariectomized beagles with calcium restriction. 1998 *J Bone Miner
385 Res*. 13(6): p. 1011-22.
- 386 23. Lafage, M.H., R. Balena, M.A. Battle, M. Shea, et al., Comparison of alendronate
387 and sodium fluoride effects on cancellous and cortical bone in minipigs. A one-
388 year study. 1995 *J Clin Invest*. 95(5): p. 2127-33.
- 389 24. Bikle, D., E. Morey-Holton, S. Doty, P. Currier, et al., Alendronate increases
390 skeletal mass of growing rats during unloading by inhibiting resorption of
391 calcified cartilage. 1994 *J Bone Miner Res*. 9(11): p. 1777-1787.
- 392 25. Iwata, K., J. Li, H. Follet, R.J. Phipps, et al., Bisphosphonates suppress periosteal
393 osteoblast activity independent of resorption in rat femur and tibia. 2006 *Bone*.
394 39(5): p. 1053-8.
- 395 26. Nakamura, M., N. Udagawa, S. Matsuura, M. Mogi, et al., Osteoprotegerin
396 regulates bone formation through a coupling mechanism with bone resorption.
397 2003 *Endocrinology*. 144(12): p. 5441-9.
- 398 27. Parfitt, A.M., Parathyroid hormone and periosteal bone expansion. 2002 *J Bone
399 Miner Res*. 17(10): p. 1741-3.
- 400 28. Dempster, D.W., F. Cosman, E.S. Kurland, H. Zhou, et al., Effects of daily
401 treatment with parathyroid hormone on bone microarchitecture and turnover in
402 patients with osteoporosis: a paired biopsy study. 2001 *J Bone Miner Res*. 16(10):
403 p. 1846-53.
- 404 29. Hodsman, A.B., M. Kiesel, J.D. Adachi, L.J. Fraher, et al., Histomorphometric
405 evidence for increased bone turnover without change in cortical thickness or
406 porosity after 2 years of cyclical hPTH(1-34) therapy in women with severe
407 osteoporosis. 2000 *Bone*. 27(2): p. 311-318.

- 408 30. Jiang, Y., J.J. Zhao, B.H. Mitlak, O. Wang, et al., Recombinant human
409 parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous
410 bone structure. 2003 J Bone Miner Res. 18(11): p. 1932-41.
- 411 31. Dempster, D., H. Zhou, F. Cosman, J. Nieves, et al., PTH treatment directly
412 stimulates bone formation in cancellous and cortical bone in humans. 2001 J Bone
413 Miner Res. 16 (Supp 1): p. S179.
- 414 32. Lindsay, R., H. Zhou, F. Cosman, J. Nieves, et al., Effects of a one-month
415 treatment with PTH(1-34) on bone formation on cancellous, endocortical, and
416 periosteal surfaces of the human ilium. 2007 J Bone Miner Res. 22(4): p. 495-
417 502.
- 418 33. Arlot, M., P.J. Meunier, G. Boivin, L. Haddock, et al., Differential effects of
419 teriparatide and alendronate on bone remodeling in postmenopausal women
420 assessed by histomorphometric parameters. 2005 J Bone Miner Res. 20(7): p.
421 1244-53.
- 422 34. Hirano, T., D.B. Burr, R.L. Cain, and J.M. Hock, Changes in geometry and
423 cortical porosity in adult, ovary-intact rabbits after 5 months treatment with
424 LY333334 (hPTH 1-34). 2000 Calcif Tissue Int. 66(6): p. 456-60.
- 425 35. Hirano, T., D.B. Burr, C.H. Turner, M. Sato, et al., Anabolic effects of human
426 biosynthetic parathyroid hormone fragment (1-34), LY333334, on remodeling and
427 mechanical properties of cortical bone in rabbits. 1999 J Bone Miner Res. 14(4):
428 p. 536-45.
- 429 36. Mashiba, T., D.B. Burr, C.H. Turner, M. Sato, et al., Effects of human parathyroid
430 hormone (1-34), LY333334, on bone mass, remodeling, and mechanical
431 properties of cortical bone during the first remodeling cycle in rabbits. 2001 Bone.
432 28(5): p. 538-47.
- 433 37. Burr, D.B., Remodeling and the repair of fatigue damage. 1993 Calcif Tissue Int.
434 53 Suppl 1: p. S75-80; discussion S80-1.
- 435 38. Seeman, E. and P.D. Delmas, Bone quality--the material and structural basis of
436 bone strength and fragility. 2006 N Engl J Med. 354(21): p. 2250-61.
- 437 39. Martin, R.B., D.B. Burr, and N.A. Sharkey, *Skeletal Tissue Mechanics*. 1998,
438 New York: Springer.
- 439 40. Tommasini, S.M., P. Nasser, B. Hu, and K.J. Jepsen, Biological co-adaptation of
440 morphological and composition traits contributes to mechanical functionality and
441 skeletal fragility. 2008 J Bone Miner Res. 23(2): p. 236-46.
- 442 41. Bell, K.L., N. Loveridge, P.C. Lindsay, M. Lunt, et al., Cortical remodeling
443 following suppression of endogenous estrogen with analogs of gonadotrophin
444 releasing hormone. 1997 J Bone Miner Res. 12(8): p. 1231-40.
- 445 42. Vedi, S., K.L. Bell, N. Loveridge, N. Garrahan, et al., The effects of hormone
446 replacement therapy on cortical bone in postmenopausal women. A
447 histomorphometric study. 2003 Bone. 33(3): p. 330-334.
- 448 43. Eriksen, E.F., F. Melsen, E. Sod, I. Barton, et al., Effects of long-term risedronate
449 on bone quality and bone turnover in women with postmenopausal osteoporosis.
450 2002 Bone. 31(5): p. 620-5.
- 451 44. Dufresne, T., P. Chmielewski, M. Manhart, T. Johnson, et al., Risedronate
452 preserves bone architecture in early postmenopausal women in 1 year as

453 measured by three-dimensional microcomputed tomography. 2003 *Calcif Tissue*
454 *Int.* 73(5): p. 423-32.

455 45. Roschger, P., S. Rinnerthaler, J. Yates, G.A. Rodan, et al., Alendronate increases
456 degree and uniformity of mineralization in cancellous bone and decreases the
457 porosity in cortical bone of osteoporotic women. 2001 *Bone*. 29(2): p. 185-91.

458 46. Itoh, F., M. Kojima, H. Furihata-Komatsu, S. Aoyagi, et al., Reductions in bone
459 mass, structure, and strength in axial and appendicular skeletons associated with
460 increased turnover after ovariectomy in mature cynomolgus monkeys and
461 preventive effects of clodronate. 2002 *J Bone Miner Res.* 17(3): p. 534-43.

462 47. Smith, S.Y., R.R. Recker, M. Hannan, R. Muller, et al., Intermittent intravenous
463 administration of the bisphosphonate ibandronate prevents bone loss and
464 maintains bone strength and quality in ovariectomized cynomolgus monkeys.
465 2003 *Bone*. 32(1): p. 45-55.

466 48. Mashiba, T., S. Hui, C.H. Turner, S. Mori, et al., Bone remodeling at the iliac
467 crest can predict the changes in remodeling dynamics, microdamage
468 accumulation, and mechanical properties in the lumbar vertebrae of dogs. 2005
469 *Calcif Tissue Int.* 77(3): p. 180-5.

470 49. Sato, M., M. Westmore, Y.L. Ma, A. Schmidt, et al., Teriparatide [PTH(1-34)]
471 strengthens the proximal femur of ovariectomized nonhuman primates despite
472 increasing porosity. 2004 *J Bone Miner Res.* 19(4): p. 623-9.

473 50. Burr, D., T. Hirano, C. Turner, C. Hotchkiss, et al., Intermittently administered
474 human parathyroid hormone(1-34) treatment increases intracortical bone turnover
475 and porosity without reducing bone strength in the humerus of ovariectomized
476 cynomolgus monkeys. 2001 *Journal of Bone and Mineral Research*. 16: p. 157-
477 165.

478 51. Boyce, R.W., C.L. Paddock, A.F. Franks, M.L. Jankowsky, et al., Effects of
479 intermittent hPTH(1-34) alone and in combination with 1,25(OH)(2)D(3) or
480 risedronate on endosteal bone remodeling in canine cancellous and cortical bone.
481 1996 *J Bone Miner Res.* 11(5): p. 600-13.

482 52. Han, Z.H., S. Palnitkar, D.S. Rao, D. Nelson, et al., Effects of ethnicity and age or
483 menopause on the remodeling and turnover of iliac bone: implications for
484 mechanisms of bone loss. 1997 *J Bone Miner Res.* 12(4): p. 498-508.

485 53. Recker, R., J. Lappe, K.M. Davies, and R. Heaney, Bone remodeling increases
486 substantially in the years after menopause and remains increased in older
487 osteoporosis patients. 2004 *J Bone Miner Res.* 19(10): p. 1628-33.

488 54. Weinstein, R.S., A.M. Parfitt, R. Marcus, M. Greenwald, et al., Effects of
489 raloxifene, hormone replacement therapy, and placebo on bone turnover in
490 postmenopausal women. 2003 *Osteoporos Int.* 14(10): p. 814-22.

491 55. Borah, B., T.E. Dufresne, P.A. Chmielewski, T.D. Johnson, et al., Risedronate
492 preserves bone architecture in postmenopausal women with osteoporosis as
493 measured by three-dimensional microcomputed tomography. 2004 *Bone*. 34(4): p.
494 736-46.

495 56. Bevill, G., S.K. Eswaran, A. Gupta, P. Papadopoulos, et al., Influence of bone
496 volume fraction and architecture on computed large-deformation failure
497 mechanisms in human trabecular bone. 2006 *Bone*. 39(6): p. 1218-25.

- 498 57. Lufkin, E.G., H.W. Wahner, W.M. O'Fallon, S.F. Hodgson, et al., Treatment of
499 postmenopausal osteoporosis with transdermal estrogen. 1992 *Ann Intern Med.*
500 117(1): p. 1-9.
- 501 58. Prestwood, K.M., M. Gunness, D.B. Muchmore, Y. Lu, et al., A comparison of
502 the effects of raloxifene and estrogen on bone in postmenopausal women. 2000 *J*
503 *Clin Endocrinol Metab.* 85(6): p. 2197-202.
- 504 59. Riggs, B.L., J. Jowsey, R.S. Goldsmith, P.J. Kelly, et al., Short- and long-term
505 effects of estrogen and synthetic anabolic hormone in postmenopausal
506 osteoporosis. 1972 *J Clin Invest.* 51(7): p. 1659-63.
- 507 60. Vedi, S. and J.E. Compston, The effects of long-term hormone replacement
508 therapy on bone remodeling in postmenopausal women. 1996 *Bone.* 19(5): p.
509 535-9.
- 510 61. Eriksen, E.F., B. Langdahl, A. Vesterby, J. Rungby, et al., Hormone replacement
511 therapy prevents osteoclastic hyperactivity: A histomorphometric study in early
512 postmenopausal women. 1999 *J Bone Miner Res.* 14(7): p. 1217-21.
- 513 62. Khastgir, G., J. Studd, N. Holland, J. Alaghband-Zadeh, et al., Anabolic effect of
514 estrogen replacement on bone in postmenopausal women with osteoporosis:
515 histomorphometric evidence in a longitudinal study. 2001 *J Clin Endocrinol*
516 *Metab.* 86(1): p. 289-95.
- 517 63. Patel, S., M. Pazianas, J. Tobias, T.J. Chambers, et al., Early effects of hormone
518 replacement therapy on bone. 1999 *Bone.* 24(3): p. 245-8.
- 519 64. Vedi, S., D.W. Purdie, P. Ballard, S. Bord, et al., Bone remodeling and structure
520 in postmenopausal women treated with long-term, high-dose estrogen therapy.
521 1999 *Osteoporos Int.* 10(1): p. 52-8.
- 522 65. Ott, S.M., A. Oleksik, Y. Lu, K. Harper, et al., Bone histomorphometric and
523 biochemical marker results of a 2-year placebo-controlled trial of raloxifene in
524 postmenopausal women. 2002 *J Bone Miner Res.* 17(2): p. 341-8.
- 525 66. Ham, K.D. and C.S. Carlson, Effects of estrogen replacement therapy on bone
526 turnover in subchondral bone and epiphyseal metaphyseal cancellous bone of
527 ovariectomized cynomolgus monkeys. 2004 *J Bone Miner Res.* 19(5): p. 823-9.
- 528 67. Allen, M.R., K. Iwata, M. Sato, and D.B. Burr, Raloxifene enhances vertebral
529 mechanical properties independent of bone density. 2006 *Bone.* 39: p. 1130-1135.
- 530 68. Chavassieux, P.M., M.E. Arlot, C. Reda, L. Wei, et al., Histomorphometric
531 assessment of the long-term effects of alendronate on bone quality and
532 remodeling in patients with osteoporosis. 1997 *J Clin Invest.* 100(6): p. 1475-80.
- 533 69. Stepan, J.J., D.B. Burr, I. Pavo, A. Sipos, et al., Low bone mineral density is
534 associated with bone microdamage accumulation in postmenopausal women with
535 osteoporosis. 2007 *Bone.* 41(3): p. 378-85.
- 536 70. Recker, R., P. Masarachia, A. Santora, T. Howard, et al., Trabecular bone
537 microarchitecture after alendronate treatment of osteoporotic women. 2005 *Curr*
538 *Med Res Opin.* 21(2): p. 185-94.
- 539 71. Recker, R.R., R.S. Weinstein, C.H. Chesnut, 3rd, R.C. Schimmer, et al.,
540 Histomorphometric evaluation of daily and intermittent oral ibandronate in
541 women with postmenopausal osteoporosis: results from the BONE study. 2004
542 *Osteoporos Int.* 15(3): p. 231-7.

- 543 72. Recker, R.R., P.D. Delmas, J. Halse, I.R. Reid, et al., Effects of intravenous
544 zoledronic acid once yearly on bone remodeling and bone structure. 2008 J Bone
545 Miner Res. 23(1): p. 6-16.
- 546 73. Balena, R., B.C. Toolan, M. Shea, A. Markatos, et al., The effects of 2-year
547 treatment with the aminobisphosphonate alendronate on bone metabolism, bone
548 histomorphometry, and bone strength in ovariectomized nonhuman primates.
549 1993 J Clin Invest. 92(6): p. 2577-86.
- 550 74. Monier-Faugere, M.C., Z. Geng, E.P. Paschalis, Q. Qi, et al., Intermittent and
551 continuous administration of the bisphosphonate ibandronate in
552 ovariectomized beagle dogs: effects on bone morphometry and mineral
553 properties. 1999 J Bone Miner Res. 14(10): p. 1768-78.
- 554 75. Allen, M.R. and D.B. Burr, Three years of alendronate treatment results in similar
555 levels of vertebral microdamage as after one year of treatment. 2007 J Bone
556 Miner Res. 22(11): p. 1759-65.
- 557 76. Allen, M.R., K. Iwata, R. Phipps, and D.B. Burr, Alterations in canine vertebral
558 bone turnover, microdamage accumulation, and biomechanical properties
559 following 1-year treatment with clinical treatment doses of risedronate or
560 alendronate. 2006 Bone. 39(4): p. 872-9.
- 561 77. Forwood, M.R., D.B. Burr, Y. Takano, D.F. Eastman, et al., Risedronate
562 treatment does not increase microdamage in the canine femoral neck. 1995 Bone.
563 16(6): p. 643-650.
- 564 78. Komatsubara, S., S. Mori, T. Mashiba, M. Ito, et al., Long-term treatment of
565 incadronate disodium accumulates microdamage but improves the trabecular bone
566 microarchitecture in dog vertebra. 2003 J Bone Miner Res. 18(3): p. 512-20.
- 567 79. Mashiba, T., C.H. Turner, T. Hirano, M.R. Forwood, et al., Effects of suppressed
568 bone turnover by bisphosphonates on microdamage accumulation and
569 biomechanical properties in clinically relevant skeletal sites in beagles. 2001
570 Bone. 28(5): p. 524-31.
- 571 80. Allen, M. and D. Burr, Parathyroid hormone and bone biomechanics. 2006
572 Clinical Reviews in Bone and Mineral Metabolism. 4(4): p. 259-268.
- 573 81. Burr, D.B., Does early PTH treatment compromise bone strength? The balance
574 between remodeling, porosity, bone mineral, and bone size. 2005 Curr Osteoporos
575 Rep. 3(1): p. 19-24.
- 576 82. Dobnig, H. and R.T. Turner, Evidence that intermittent treatment with parathyroid
577 hormone increases bone formation in adult rats by activation of bone lining cells.
578 1995 Endocrinology. 136(8): p. 3632-8.
- 579 83. Hodsman, A.B. and B.M. Steer, Early histomorphometric changes in response to
580 parathyroid hormone therapy in osteoporosis: evidence for de novo bone
581 formation on quiescent cancellous surfaces. 1993 Bone. 14(3): p. 523-7.
- 582 84. Reeve, J., P.J. Meunier, J.A. Parsons, M. Bernat, et al., Anabolic effect of human
583 parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a
584 multicentre trial. 1980 Br Med J. 280(6228): p. 1340-4.
- 585 85. Miki, T., K. Nakatsuka, H. Naka, H. Masaki, et al., Effect and safety of
586 intermittent weekly administration of human parathyroid hormone 1-34 in
587 patients with primary osteoporosis evaluated by histomorphometry and

588 microstructural analysis of iliac trabecular bone before and after 1 year of
589 treatment. 2004 J Bone Miner Metab. 22(6): p. 569-76.

590 86. Jerome, C.P., C.S. Johnson, H.T. Vafai, K.C. Kaplan, et al., Effect of treatment
591 for 6 months with human parathyroid hormone (1-34) peptide in ovariectomized
592 cynomolgus monkeys (*Macaca fascicularis*). 1999 Bone. 25(3): p. 301-9.

593 87. Delmas, P.D., P. Vergnaud, M.E. Arlot, P. Pastoureau, et al., The anabolic effect
594 of human PTH (1-34) on bone formation is blunted when bone resorption is
595 inhibited by the bisphosphonate tiludronate--is activated resorption a prerequisite
596 for the in vivo effect of PTH on formation in a remodeling system? 1995 Bone.
597 16(6): p. 603-10.

598 88. Zhang, L., H.E. Takahashi, J. Inoue, T. Tanizawa, et al., Effects of intermittent
599 administration of low dose human PTH(1-34) on cancellous and cortical bone of
600 lumbar vertebral bodies in adult beagles. 1997 Bone. 21(6): p. 501-6.

601 89. Jerome, C.P., D.B. Burr, T. Van Bibber, J.M. Hock, et al., Treatment with human
602 parathyroid hormone (1-34) for 18 months increases cancellous bone volume and
603 improves trabecular architecture in ovariectomized cynomolgus monkeys
604 (*Macaca fascicularis*). 2001 Bone. 28(2): p. 150-159.

605 90. Sato, M., M. Westmore, J. Clendenon, S. Smith, et al., Three-dimensional
606 modeling of the effects of parathyroid hormone on bone distribution in lumbar
607 vertebrae of ovariectomized cynomolgus macaques. 2000 Osteoporos Int. 11(10):
608 p. 871-80.

609
610

